NCT04153565 2025-07-17
MK-3475-A17
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
10 trialsNCT04158141 2025-02-19
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Phase 3 Terminated
NCT02784171 2024-12-10
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2/3 Completed
NCT03319537 2024-05-23
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT02899299 2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3 Completed
NCT00101283 2023-07-03
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00295503 2020-10-20
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated
NCT00604461 2017-03-23
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00316225 2010-07-09
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Eli Lilly and Company
Phase 2 Completed